JAZZ - Jazz updates 2021 financial guidance adding impact of GW Pharma acquisition

Zhanna Hapanovich/iStock via Getty Images Jazz Pharmaceuticals (JAZZ) estimates ~18.1% of additional revenue in 2021 as a result of the acquisition of GW Pharmaceuticals (GWPH), the updated financial guidance issued by the company for this year indicates. Including the projected results from GW Pharma from May 5, 2021, to December 31, 2021, the company now expects $3.1B of revenue in 2021 at the mid-point, ~18.1% higher than the previous guidance announced on May 04. Compared to ~$2.4B in revenue recorded by Jazz in 2020, the updated revenue guidance indicates a ~31.2% YoY growth compared to ~31.5% YoY growth in the consensus. Total net product sales are estimated at ~$3.1B at the midpoint of the guidance with the addition of ~17.8% more sales compared to the previous guidance. With ~$2.3B in sales at the midpoint, neuroscience is expected to make up ~74.8% of total net product sales compared to ~70.0% previously. SG&A and RD

For further details see:

Jazz updates 2021 financial guidance adding impact of GW Pharma acquisition